Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis
Annarosa Floreani1,2 1University of Padova, Padova, Italy; 2Scientific Institute for Research, Hospitalization and Healthcare, Negrar, Verona, ItalyCorrespondence: Annarosa FloreaniUniversity of Padova, Padova, ItalyTel +10393899418841Email annarosa.floreani@unipd.itAbstract: The standard therapy fo...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-12-01
|
| Series: | Journal of Experimental Pharmacology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/experimental-pharmacological-agents-for-the-treatment-of-primary-bilia-peer-reviewed-fulltext-article-JEP |
| _version_ | 1818903938444820480 |
|---|---|
| author | Floreani A |
| author_facet | Floreani A |
| author_sort | Floreani A |
| collection | DOAJ |
| description | Annarosa Floreani1,2 1University of Padova, Padova, Italy; 2Scientific Institute for Research, Hospitalization and Healthcare, Negrar, Verona, ItalyCorrespondence: Annarosa FloreaniUniversity of Padova, Padova, ItalyTel +10393899418841Email annarosa.floreani@unipd.itAbstract: The standard therapy for primary biliary cholangitis (PBC) is ursodeoxycholic acid (UDCA) which has shown to improve hepatic biochemistry, delay histological progression and improve transplant-free survival. Approximately 30– 40% of patients do not respond or are intolerant to UDCA. Obeticholic acid, a farnesoid X receptor (FXR) agonist is the only agent approved by the Food and Drug Administration for patients who do not respond to UDCA. Recently, combination therapy with UDCA and bezafibrate has been shown to improve biochemistry and both GLOBE and UK-PBC score in patients with an inadequate response to UDCA. More recently, new pharmacological agents have been included in Phase 2 and Phase 3 trials: PPAR agonists, non-bile acid FXR agonists, anti-NOX agents, immunomodulators and mesenchymal stem cells transplantation. This review gives an overview on the current experimental pharmacological agents employed in the treatment of PBC.Keywords: PBC, treatment, ursodeoxycholic acid, obeticholic acid, fibrates, FXR agonists, PPAR agonists |
| first_indexed | 2024-12-19T20:59:30Z |
| format | Article |
| id | doaj.art-4885e2b0ab864819ba2e9e69d755acf2 |
| institution | Directory Open Access Journal |
| issn | 1179-1454 |
| language | English |
| last_indexed | 2024-12-19T20:59:30Z |
| publishDate | 2020-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Experimental Pharmacology |
| spelling | doaj.art-4885e2b0ab864819ba2e9e69d755acf22022-12-21T20:05:50ZengDove Medical PressJournal of Experimental Pharmacology1179-14542020-12-01Volume 1264365260453Experimental Pharmacological Agents for the Treatment of Primary Biliary CholangitisFloreani AAnnarosa Floreani1,2 1University of Padova, Padova, Italy; 2Scientific Institute for Research, Hospitalization and Healthcare, Negrar, Verona, ItalyCorrespondence: Annarosa FloreaniUniversity of Padova, Padova, ItalyTel +10393899418841Email annarosa.floreani@unipd.itAbstract: The standard therapy for primary biliary cholangitis (PBC) is ursodeoxycholic acid (UDCA) which has shown to improve hepatic biochemistry, delay histological progression and improve transplant-free survival. Approximately 30– 40% of patients do not respond or are intolerant to UDCA. Obeticholic acid, a farnesoid X receptor (FXR) agonist is the only agent approved by the Food and Drug Administration for patients who do not respond to UDCA. Recently, combination therapy with UDCA and bezafibrate has been shown to improve biochemistry and both GLOBE and UK-PBC score in patients with an inadequate response to UDCA. More recently, new pharmacological agents have been included in Phase 2 and Phase 3 trials: PPAR agonists, non-bile acid FXR agonists, anti-NOX agents, immunomodulators and mesenchymal stem cells transplantation. This review gives an overview on the current experimental pharmacological agents employed in the treatment of PBC.Keywords: PBC, treatment, ursodeoxycholic acid, obeticholic acid, fibrates, FXR agonists, PPAR agonistshttps://www.dovepress.com/experimental-pharmacological-agents-for-the-treatment-of-primary-bilia-peer-reviewed-fulltext-article-JEPpbctreatmentursodeoxycholic acidobeticholic acidfibratesfxr agonistsppar agonists |
| spellingShingle | Floreani A Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis Journal of Experimental Pharmacology pbc treatment ursodeoxycholic acid obeticholic acid fibrates fxr agonists ppar agonists |
| title | Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis |
| title_full | Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis |
| title_fullStr | Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis |
| title_full_unstemmed | Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis |
| title_short | Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis |
| title_sort | experimental pharmacological agents for the treatment of primary biliary cholangitis |
| topic | pbc treatment ursodeoxycholic acid obeticholic acid fibrates fxr agonists ppar agonists |
| url | https://www.dovepress.com/experimental-pharmacological-agents-for-the-treatment-of-primary-bilia-peer-reviewed-fulltext-article-JEP |
| work_keys_str_mv | AT floreania experimentalpharmacologicalagentsforthetreatmentofprimarybiliarycholangitis |